Wire · operational-macro
Trinity Biotech (NASDAQ: TRIB) ends $25M standby share deal
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 August 2026 · Fusion42 review
Trinity Biotech terminated its $25 million standby equity purchase agreement with YA II PN, LTD., deregistering 675 million ordinary shares previously registered but unsold, and implemented a one-for-thirty reverse ADS split changing the ADS ratio from 20 to 600 ordinary shares per ADS.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You have a window to approach investors about new equity offerings as deregistration clears regulatory hurdles and the reverse ADS split may improve investor perception. This changes your capital access strategy and share liquidity considerations requiring swift adjustment.
◆ Coverage
1 source · 21 Aug 2026
◆ Related on Wire
◆ Topics